R

Revolution Medicines
D

RVMD

41.360
USD
-0.89
(-2.11%)
Market Closed
Volume
34,330
EPS
-4
Div Yield
-
P/E
-11
Market Cap
7,643,141,011
Related Instruments
    A
    ARWR
    -1.040
    (-4.97%)
    19.900 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    I
    IONS
    -0.365
    (-1.12%)
    32.310 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    R
    RARE
    -1.920
    (-4.31%)
    42.590 USD
    R
    RGEN
    -3.710
    (-2.28%)
    158.950 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    More
News

Title: Revolution Medicines

Sector: Healthcare
Industry: Biotechnology
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.